Trial Profile

Phase 1 Study of CART-BCMA With or Without huCART19 as Consolidation of Standard First or Second-Line Therapy for High-Risk Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CTL 119 (Primary) ; MTV-273 (Primary) ; Cyclophosphamide; Fludarabine
Indications Multiple myeloma
Focus Adverse reactions

Most Recent Events

28 Jun 2021 Planned End Date changed from 9 May 2036 to 1 Mar 2036.
28 Jun 2021 Planned primary completion date changed from 9 May 2022 to 1 Mar 2036.
27 May 2021 Planned primary completion date changed from 9 May 2021 to 9 May 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com